Novo Nordisk Faces a High-Stakes Balancing Act: Wegovy Pill Approval vs. Escalating Cyber Threats
Published on 06/22/2026 at 07:53 | Redaktion boerse-global.de
Novo Nordisk ended a week of stark contrasts with its shares stuck near EUR 38.90 — a modest 2.6% gain — as investors weighed a major regulatory win against a deepening cybersecurity crisis. The Danish drugmaker’s oral Wegovy pill won approval from the UK’s MHRA for weight reduction, making Britain the first European market to clear the tablet. The decision landed just days after two hacker groups publicly pressed the company for tens of millions of dollars.
The breakthrough rests on the OASIS-4 study, in which patients taking the pill lost an average of 13.6% of their body weight, compared with 2.2% for the placebo group. Novo Nordisk now intends to seek approval in China, where the oral formulation could help offset the expiration of the semaglutide patent in March 2026. Generics are expected to enter that market as early as the second quarter of 2027. CEO Mike Doustdar, visiting Peking, confirmed the filing timeline, though rival Eli Lilly has already submitted its own once-daily oral obesity therapy to Chinese regulators.
The cybersecurity saga, by contrast, has clouded the narrative. Novo Nordisk disclosed a breach on June 11, saying intruders had copied internal documents — including data from clinical trial participants — and temporarily shut down some systems. By June 17, two groups had emerged with ransom demands: FulcrumSec is asking for $25 million, while TheUSERS007 has set a $50 million price tag. The company has refused to pay. Regulators are now scrutinising the incident for potential violations of the EU’s General Data Protection Regulation, which could impose fines of up to 4% of global annual turnover.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Beyond the immediate crisis, the company is laying groundwork for the next generation of therapies. On June 21, the Novo Nordisk Foundation launched the “CardioMetabolic Bridge” network, a EUR 450 million (approx. DKK 450 million) research consortium linking European universities and startups over six years, with initial hubs in Germany, Italy and London. Though the foundation is legally independent of the listed group, the network serves as an early-warning system for new drug targets — particularly relevant as analysts flag the potential 2031 patent cliff for Ziltivekimab.
Manufacturing capacity is also getting a boost. On June 19, Novo Nordisk began production at a newly acquired facility in Bohumil, Czech Republic. The plant, bought from Novavax for $360 million at the end of 2024, will produce helper proteins for next-generation diabetes and obesity medicines. In the US, two major projects are underway: integrating the Bloomington, Indiana, site and a multibillion-dollar expansion in Clayton, North Carolina, due to peak in summer 2027 and tied directly to sustained demand for GLP-1 therapies.
The stock’s weekly advance still leaves it down roughly 13% year-to-date and more than 36% below the 52-week high of EUR 61.20. The long shadow of the record level from mid-2025 underscores the pressure on management to turn regulatory wins into revenue quickly, while the potential costs of the data breach threaten to slow that recovery. For now, the market remains in wait-and-see mode — cheered by the pill’s progress, but wary of the digital dangers behind the scenes.
Ad
Novo Nordisk Stock: New Analysis - 22 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
